In Genome Research this week: long-read Caenorhabditis elegans sequences, enhancer patterns in breast cancer cell lines, and more.
Two speakers at the National Society of Genetic Counselors annual meeting discussed how often genetic variants are reclassified and how that affects patients.
Investigators will use Biocept's liquid biopsy tests to detect ALK rearrangements both at baseline and to monitor treatment response and resistance mechanisms.
New data from Peregrine Pharmaceuticals, along with other recent research, suggests that surface proteins can be used to isolate cancer-specific exosomes to detect the presence of a tumor.
Exonics will use the funding to advance preclinical research from UT-Southwestern researcher Eric Olson on genome editing of DMD mutations in a mouse model.
UT-SWMC researcher Eric Olson will study dystrophin produced with CRISPR/Cas9 genome editing in a mouse model, as well as off-target effects.
Researchers link two genes to sleep regulation, according to Medical News Today.
In Science this week: convergent evolution in bird hemoglobin, and more.
The partners have a long-standing sponsored research agreement focused on phosphatidylserine, a signaling molecule found in tumor exosomes.
The peptide may be a new therapeutic target for heart failure patients and suggests that similar ncRNA-encoded proteins with important functions may exist.
Direct-to-consumer genetic testing companies have offered to test families separated at the southern US border, but that raises ethical issues.
CNBC reports that confirming a positive result from 23andMe's BRCA health report can be expensive.
The New York Times reports on a project to develop a tree DNA database to uncover illegal logging.
In PLOS this week: links between gut microbiome and colorectal cancer mutations, targeted sequencing uncovers genetic susceptibilities to epilepsy in Koreans, and more.